PAVmed Issues Series Z Warrants to Purchase Common Stock

TL;DR

**PAVmed just issued new warrants, watch for potential dilution.**

AI Summary

PAVmed Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 5, 2024. This filing indicates that the company issued Series Z Warrants to purchase common stock, alongside its existing common stock with a par value of $0.001 per share. This matters to investors because the issuance of new warrants could lead to dilution of existing shares if exercised, potentially impacting the stock price and ownership percentage for current shareholders.

Why It Matters

The issuance of Series Z Warrants could dilute existing shareholders if exercised, potentially impacting the stock's value and future earnings per share.

Risk Assessment

Risk Level: medium — The issuance of warrants introduces potential future dilution, which is a moderate risk for existing shareholders.

Analyst Insight

Investors should monitor the terms of the Series Z Warrants, including exercise price and expiration date, to assess the potential for future dilution and its impact on share value.

Key Numbers

• $0.001 — Common Stock Par Value (The par value of PAVmed's common stock per share.)

Key Players & Entities

• PAVmed Inc. (company) — Registrant filing the 8-K
• $0.001 (dollar_amount) — Par value per share of common stock
• January 5, 2024 (date) — Date of earliest event reported
• January 8, 2024 (date) — Date of 8-K filing

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, Par Value $0.001 Per Share PAVM The Nasdaq Stock Mar
• $1 m — ompany had regained compliance with the $1 minimum bid price requirement for continu
• $1 — mon stock had been below the minimum of $1 per share required for continued listin

Filing Documents

• form8-k.htm (8-K) — 45KB
• 0001493152-24-001710.txt ( ) — 257KB
• pavm-20240105.xsd (EX-101.SCH) — 4KB
• pavm-20240105_def.xml (EX-101.DEF) — 26KB
• pavm-20240105_lab.xml (EX-101.LAB) — 36KB
• pavm-20240105_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 5KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2024 PAVMED INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37685 47-1214177 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 360 Madison Avenue , 25th Floor , New York , New York 10017 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (917) 813-1828 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.001 Per Share PAVM The Nasdaq Stock Market LLC Series Z Warrants to Purchase Common Stock PAVMZ The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01. Other Events. On January 7, 2024, PAVmed Inc. (the " Company ") received a notification letter from the Listing Qualifications department of The Nasdaq Stock Market LLC (" Nasdaq "), dated January 5, 2024, stating that the Company had regained compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market. As previously reported, on December 29, 2022, the Company had received a notification letter from the Listing Qualifications department stating that, for the prior 30 consecutive business days (through December 28, 2022), the closing bid price of the Company's common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Subsequently, Nasdaq determined that, from December 7, 2023 to January 5, 2024, the closing bid price of the Company's common stock had been at $1 per share or greater. Accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2). Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2024 PAVMED INC. By: /s/ Dennis M. McGrath Dennis M. McGrath President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR